Clinical Trials | A Phase 1b/2 Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bispecific CAR-T Cell Therapy in Adult Participants with B-cell Non-Hodgkin Lymphoma

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with relapsed or refractory B-cell non-Hodgkin lymphoma for a research study. The purpose of the study is to find out if the investigational drug JNJ-90014496 is effective for the treatment of B-cell non-Hodgkin lymphoma and to further understand what side effects it may cause. JNJ-90014496 will be manufactured for each participant from T cells collected from eligible participants =18 years of age with a diagnosis of r/r LBCL, FLBL, or transformation of indolent lymphoma. All participants must have received =2 prior lines of systemic therapy. Two cohorts will be evaluated: Cohort A (CAR-T Naive) will enroll participants who have not previously been treated with CAR-T cell therapy; Cohort B (CAR-T Exposed) will enroll participants with relapsed disease after previous treatment with CAR-T cell therapy If you join the study, you will be on the study for at least 2 years after dosing of JNJ-90014496